Saratov JOURNAL of Medical and Scientific Research

Assessment of range of uric and serum biomarkers in determination of bladder cancer severity

Year: 2013, volume 9 Issue: №4 Pages: 735-740
Heading: Urology Article type: Original article
Authors: Popkov V.M., Ponukalin A.N. Zakharova N.B.
Organization: Saratov State Medical University
Summary:

Purpose: to establish efficiency of a range of uric and serum biomarkers of bladder cancer for diagnostics and the prognosis of risk of development of disease recurrence. Material and methods: TPA and TPS, VEGF level research in blood serum, UBC in urine in 176 people, among which 135 patients with bladder cancer (RMP) have been conducted. Group of comparison has included16 patients (patients with cystitis). The control group has been made of 25 almost healthy men. 75 patients had non-muscle invasive RMP (Ta-1N0M0). Results. It has been statistically determined that reliable growth of of TPA, TPS in blood serum and UBC in urine in patients with non-muscle invasive RMP in comparison with patients in groups of control and comparison has been established. The increase of UBC in urine of patients of this group with recurrence of tumoral growth within a year has been noted. In comparison with cytological research of urine sedimentation, molecular markers of RMP (the uric UBC and serum TPA, TPS) possess diagnostic sensitivity, allow to confirm the presence of disease, to carry out diagnostics of stages of organ and extra invasion. RMP is possible to consider as an additional prognostic serum marker increase in the VEGF level in blood serum. Conclusion. Inclusion in diagnostic process in the clinical research of biomarkers showed that identification of NMIRMP increased from 18,1% in 2006 to 55,6% in 2011. The chosen volume of complex treatment allowed to reduce recurrence and lethality in the first two years from 32 to 15,5%.

Bibliography:
1. Bladder tumor markers: a review of the literature /A. Volpe [et al.] // The International Journal of Biological Markers. 2008. Vol. 23 (4). P. 249-261; 2. Goebell P. J., Knowles M.A. Bladder cancer or bladder cancers? Genetically distinct malignant conditions on the urothelium // Urol. Oncol. 2010. № 28 (4). R. 409-428; 3. Prognosticheskie molekuljarno-geneticheskie markery raka mochevogo puzyrja (obzor literatury) / S. А. АГ — Shukri, V N. Tkachuk, N.M. Volkov, M.V Dubina / Onkologija. 2009. № 2. S. 78-84; 4. Kushlinskij N.E., Gershtejn E.S. Biologicheskie markery opuholej v klinike: dostizhenija, problemy, perspektivy // Molekul-jarnaja medicina. 2008. № 3. S. 48-55; 5. Shirodkar S. P., Lokeshwar V B. Bladder tumor markers: from hematuria to molecular diagnostics where do we stand? // Expert review of Anticancer Therapy. 2008. Vol. 8 (7). P. 1111-1123; 6. Jacobs L.B., Lee T.C., Montie J.E. Bladder cancer in 2010: how far have we come?//CA Cancer J. Clin. 2010. №60. R. 244-272; 7. Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma/A. Stenzl, N.C. Cowan, M. De Santis [et al.] /Actas Urol. Esp. 2010, Jan. Vol. 34 (1). P. 51-62; 8. Znachenie markerov opuholevogo rosta i angiogeneza v diagnostike raka mochevogo puzyrja / P. V Glybochko, A. N. Po-nukalin, N.B. Zaharova, N.K. Shahapazjan // Onkourologija.2009. № 2. S. 56-60; 9. Klinicheskoe primenenie FISH-metoda v rannej diagnostike poverhnostnogo raka mochevogo puzyrja /A. V Sevan'kaev, E.F. Lushnikov, O.B. Karjakin [i dr] / Onkourologija. 2008. № 4. S. 61-65; 10. Molekuljarno-geneticheskie markery kak faktory prognoza techenija poverhnostnogo raka mochevogo puzyrja / A.Ju. Babajan, S. V Bashkatov, O.B. Karjakin [i dr.] / Onkourologija. 2009. №3. S. 19-24; 11. Harper J., Moses M.A. Molecular regulation of tumor angiogenesis: mechanism and therapeutic implication // EXS. 2006. Vol. 96. P. 223-268; 12. Konety B.R., Lotan Y Urothelial bladder cancer: biomarkers for detection and screening // BJU International. 2008. Vol. 102 (9 PtB). P. 1234-1241; 13. Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer: comparison with serum levels of sialic acid, TPS and CYFRA 21-1 // J. de Castro [et al.] // Cancer Invest. 2008. Vol. 26 (4). P. 407-418; 14. The value of combined use of surviving, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine /X.Y. Pu[etal.]//J. Cancer Res. Clin. Oncol. 2008. Vol. 134(6). P. 659-665.

AttachmentSize
2013-04_735-740.pdf571.73 KB

No votes yet